Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.
Alligator Bioscience AB has announced a rights issue of units worth approximately SEK 120 million, subject to approval at an extraordinary general meeting. The funds raised will be used to repay loans and support ongoing projects, including securing a partnership for mitazalimab. The rights issue is partially covered by subscription undertakings and guarantee commitments, and the company has also secured bridge loans to meet liquidity needs until the rights issue is completed.
More about Alligator Bioscience AB
Alligator Bioscience AB operates in the biotechnology industry, focusing on developing innovative antibody-based therapies for cancer treatment. The company is committed to advancing its pipeline projects and securing partnerships to enhance its market presence.
Average Trading Volume: 609,877
Technical Sentiment Signal: Sell
Current Market Cap: SEK143.7M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.